CN110300745A - 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 - Google Patents

钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 Download PDF

Info

Publication number
CN110300745A
CN110300745A CN201880010536.8A CN201880010536A CN110300745A CN 110300745 A CN110300745 A CN 110300745A CN 201880010536 A CN201880010536 A CN 201880010536A CN 110300745 A CN110300745 A CN 110300745A
Authority
CN
China
Prior art keywords
crystal form
compound
formula
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880010536.8A
Other languages
English (en)
Other versions
CN110300745B (zh
Inventor
王峥
江涛涛
王吉标
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO Ltd
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN110300745A publication Critical patent/CN110300745A/zh
Application granted granted Critical
Publication of CN110300745B publication Critical patent/CN110300745B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种钠离子通道抑制剂及其药学上可接受的盐和多晶型物，所述钠离子通道抑制剂如式(X)所示的化合物。该钠离子通道抑制剂的方法，其多晶型物及制备方法，以及其药物组合物。所述化合物和药物组合物用于治疗疼痛、抑郁症、心血管疾病、呼吸系统疾病或精神疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880010536.8A 2017-07-24 2018-06-26 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 Active CN110300745B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017106073090 2017-07-24
CN201710607309 2017-07-24
PCT/CN2018/092895 WO2019019851A1 (zh) 2017-07-24 2018-06-26 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用

Publications (2)

Publication Number Publication Date
CN110300745A true CN110300745A (zh) 2019-10-01
CN110300745B CN110300745B (zh) 2023-03-31

Family

ID=65039958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010536.8A Active CN110300745B (zh) 2017-07-24 2018-06-26 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用

Country Status (3)

Country Link
US (1) US10947202B2 (zh)
CN (1) CN110300745B (zh)
WO (1) WO2019019851A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020192553A1 (zh) * 2019-03-22 2020-10-01 上海海雁医药科技有限公司 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078374A1 (en) * 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016124139A1 (zh) * 2015-02-04 2016-08-11 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
CN108430969B (zh) * 2016-02-03 2020-06-02 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078374A1 (en) * 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016124139A1 (zh) * 2015-02-04 2016-08-11 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
WO2016124140A1 (zh) * 2015-02-04 2016-08-11 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途
CN108430969B (zh) * 2016-02-03 2020-06-02 上海海雁医药科技有限公司 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途

Also Published As

Publication number Publication date
CN110300745B (zh) 2023-03-31
WO2019019851A1 (zh) 2019-01-31
US10947202B2 (en) 2021-03-16
US20200048209A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
US9174973B2 (en) Crystalline forms of azilsartan and preparation and uses thereof
US11149017B2 (en) Solid state forms of apalutamide
NO341930B1 (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
CN107531678A (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
US20180282310A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US11634388B2 (en) Crystal form of lenvatinib mesylate and preparation method therefor
US20080027223A1 (en) Polymorphs of eszopiclone malate
CN109153656A (zh) 他发米帝司葡甲胺盐的晶型e及其制备方法和用途
CN108602772A (zh) 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺盐新晶型
CN110300745A (zh) 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2020244349A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
US20220227777A1 (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
US20220389012A1 (en) Salts of a compound and the crystalline forms thereof
WO2021230198A1 (ja) ジヒドロキノリノン化合物の共結晶
AU2017238341A1 (en) Physical form of a SGR modulator
KR20210148110A (ko) Jak2 저해제의 결정 형태
US20210188813A1 (en) Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor
RU2810067C2 (ru) Соединение ингибитора FGFR в твердой форме и способ его получения
TWI826013B (zh) 咪唑啉酮衍生物的晶型
CN114773211B (zh) 一种葡甲胺盐的晶型、其制备方法及应用
CN111601793B (zh) 苯并二环烷烃衍生物的药学上可接受的盐及其多晶型物及其应用
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
JP5077232B2 (ja) ベンゾオキサジアゾール誘導体の結晶
US20070225507A1 (en) Process for preparing a crystalline form of Tegaserod maleate
US20230106142A1 (en) Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20221020

Address after: No.8, Lane 67, libing Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant after: YANGTZE RIVER PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL Co.,Ltd.

Address before: No.8, Lane 67, libing Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd.

Applicant before: YANGTZE RIVER PHARMACEUTICAL GROUP Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant